Essential Partners’s Spyre Therapeutics SYRE Stock Holding History

Essential Partners’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$178	Hold	2	–	–	﹤0.01%	2661
2026 Q1	$101	Buy	+2	New	+$75	﹤0.01%	2713

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Essential Partners's SYRE Position: Q2 2026 in Review

Essential Partners held its Spyre Therapeutics (SYRE) position steady in Q2 2026 at 2 shares worth $178. The position accounts for ﹤0.01% of the portfolio, ranked #2661.

Essential Partners first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Essential Partners held 2 shares of Spyre Therapeutics worth $178 as of Q2 2026.
Essential Partners left its Spyre Therapeutics share count unchanged in Q2 2026.
Spyre Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2661 holding.
Essential Partners first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.